0.36
+1.43%
Close of 6 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Defence Therapeutics
Its shares trade on Canadian Securities Exchange under the ticker DTC.CN. It has been listed since 7 May 2021.
Defence Therapeutics, Inc. engages in the research and development of anti-body drug conjugates. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-05-07. The firm is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. Its platform's core is the Accum technology, which enables delivery of vaccine antigens or ADCs in their intact form to target cells. The firm is focused on research, development and advancement of various products using its Accum technology, which include Dendritic Cell cancer vaccines using Accum (Accuvac); a new protein-based vaccine formulation against COVID and infectious diseases; ADC targeting various cancers; anti-cancer AccuTOX program; cervical cancer vaccine; mesenchymal stromal cell-based vaccine (ARM) targeting cancer, and messenger ribonucleic acid vaccination.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 May 2021
Leadership
Pay as last reported
- Mr. Sebastien PlouffePresident, Chief Executive Officer, Director, since 2020C$255,000
- Mr. Arnab DeChief Financial Officer, Corporate Secretary, since 2024
- Dr. Maxime ParisottoChief Scientific Officer, Director of Science and Business Development
- Dr. Amie PhinneyDirector
- Dr. Elias TheodorouDirector
- Dr. Philippe LefrancoisIndependent Director
- Dr. Sarkis MeterissianIndependent Director
- Dr. Svetlana SelivanovaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Defence Therapeutics Inc. focuses on innovative anti-body drug conjugates for cancer treatment.
- The Accum technology platform enhances efficacy and safety of biological drugs.
- Defence Therapeutics Inc. develops multiple products including Accuvac and AccuTOX programs.
Weaknesses
- Defence Therapeutics Inc. has a limited product portfolio in the biotechnology sector.
- The company's IPO was in 2021, indicating early-stage development.
- Defence Therapeutics Inc. operates in a highly competitive Health Care industry.
Opportunities
- Defence Therapeutics Inc. can expand its Accum technology to new cancer treatments.
- The global biotechnology market offers growth potential for innovative drug platforms.
- Defence Therapeutics Inc. may partner with pharmaceutical companies for vaccine development.
Threats
- Defence Therapeutics Inc. faces regulatory challenges in the Health Care sector.
- The biotechnology industry experiences high R&D costs and long development cycles.
- Defence Therapeutics Inc. competes with established pharmaceutical firms in vaccine development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.